Drug
TTI-101
Status:
Phase 2
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
TTI-101 is a tablet taken twice daily, which targets the protein, STAT3. STAT3 plays a critical role in many of the processes that drive the development and progression of idiopathic pulmonary fibrosis (IPF), including clotting and coagulation, inflammatory cell migration, fibroblast proliferation, and extra-cellular matrix deposition.
Study Purpose
The REVERT-IPF study is evaluating the safety and effectiveness of TTI-101 with or without nintedanib (OFEV®) in patients diagnosed with IPF.